Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Back to dashboard
Company Information
About this company
Key people
Briggs W. Morrison
Independent Chairman of the Board
Randy Teel
President, Chief Executive Officer, Director
Andrew Saik
Chief Financial Officer, Treasurer, Principal Financial Officer
Angela Cacace
Chief Scientific Officer
John G. Houston
Director
Linda C. Bain
Independent Director
Everett V. Cunningham
Independent Director
Edward Kennedy
Independent Director
Leslie V. Norwalk
Independent Director
Click to see more
Key facts
- Shares in issue75.39m
- EPICARVN
- ISINUS04335A1051
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$499.55m
- Employees246
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.